Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.80 USD
Change Today +0.0021 / 0.26%
Volume 548.0
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

isatori inc (IFIT) Key Developments

iSatori, Inc. Provides Earnings Guidance for the First Quarter Ended March 31, 2015

iSatori, Inc. provided earnings guidance for the first quarter ended March 31, 2015. For the quarter, the company's total revenue, after discounts, trade promotions, and retail allowances, is estimated to be approximately $3.4 million compared to $3.2 million a year ago. A positive net income is estimated to be reported.

iSatori, Inc. Announces the Removal of the Weight-Loss Supplement MX-LS7(TM) v2 from the Supplement Market

iSatori, Inc. announced the removal of the weight-loss supplement MX-LS7(TM) v2 from the supplement market, accelerating the previously planned deletion of the item. Although an ingredient in question, Acacia rigidula, only makes up a small percentage of the total MX-LS7(TM)v2 formula and appears to be DSHEA compliant, out of precaution, iSatori is ceasing its distribution and sales of MX-LS7(TM)v2.

iSatori, Inc. Announces Management Changes

iSatori, Inc. announced that on April 3, 2015, Michael Wilemon informed the company of his retirement as the company's Chief Financial Officer. Seth Yakatan, a current member of the company's Board of Directors, has been appointed to serve as the company's Interim Chief Financial Officer, and in that capacity, he will serve as the company's principal financial officer and principal accounting officer. Andrea Clem, the company's current Controller, has been appointed Executive Vice President of Finance and will assume the day-to-day financing and accounting roles under the direction of Mr. Yakatan. Mr. Yakatan has served as a director of the company since September 16, 2014 and currently also serves as Vice President of Business Development for Invion Ltd. Mr. Yakatan brings more than 24 years of experience as a life sciences business development and corporate finance professional, actively supporting small cap and major companies in achieving corporate, financing, and asset monetization objectives. Prior to founding Katan Associates in 2001, Mr. Yakatan worked in merchant banking at Union Bank of California, N.A., in the Specialized Lending Media and Telecommunications Group. Andrea has been with iSatori for almost 10 years, first as Accounting Manager and then Controller She previously served Aspen Healthcare, as a Financial Analyst, and Lafarge North America, as a Regional Level Accountant for its Ready Mix product line.

iSatori, Inc. Announces Earnings Results for the Full Year Ended December 31, 2014

iSatori, Inc. announced earnings results for the full year ended December 31, 2014. For the year, the company reported total revenue of $9,654,788 compared to $10,665,038 a year ago. Loss from operations was $1,087,145 compared to $919,017 a year ago. Loss before income taxes was $891,712 compared to $955,814 a year ago. Net loss was $1,170,409 or $0.09 per basic and diluted share compared to $958,642 or $0.08 per basic and diluted share a year ago. Net product revenues, after discounts, returns, and marketing trade promotions, for the year ended December 31, 2014 were $9,513,606 compared with net product revenues of $10,507,038 in 2013. The reduction in revenues is primarily a result of an industry-wide disruption in the dietary supplement weight-loss segment of its business beginning in the third quarter and running through the fourth quarter 2014, compounded with a non-reoccurring, but an unplanned substantial product return from a retail customer.

iSatori, Inc. Launches its Newest Patented Weight Loss Pill DygloTrim(TM) with Dyglomera(r), Under the Biogenetics Brand, to Retail Stores Nationwide

iSatori, Inc. announced the launch of its new weight-loss innovation called DygloTrim, featuring patented Dyglomera(r). The Company has built a strong reputation for creating scientifically engineered, clinically effective weight-loss supplements through its BioGenetic Laboratories division, as evidenced by its numerous top-selling diet support supplements. The Company has already received sizable orders from GNC for Dyglotrim(TM), and recently shipped those orders.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IFIT:US $0.80 USD +0.0021

IFIT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.85 USD -0.15
USANA Health Sciences Inc $117.08 USD -0.82
Vitamin Shoppe Inc $42.31 USD -0.02
View Industry Companies
 

Industry Analysis

IFIT

Industry Average

Valuation IFIT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISATORI INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.